By: Tatjana Josifova a,*, Katarzyna Konieczka b,c, Andreas Sch€otzau d, Josef Flammer b
a Eye Clinic Orasis, Department for Medical and Surgical Retina, Reinach, Switzerland
b Department of Ophthalmology, University of Basel, Switzerland
c Glaucoma Eye Practice Dr. K. Konieczka, Basel, Switzerland
d Statistical Consulting, University of Basel, Switzerland
A B S T R A C T
Background: Patients with nAMD often have pathologically elevated homocysteine (Hcy) and increased retinal
venous pressure (RVP). We tested whether the administration of a specific vitamin preparation containing L-methylfolate
(Ocufolin forte) As an addition to anti-VEGF therapy, it reduces these two risk factors and favorably influences the disease course.
Methods: A total of 27 eyes/27 patients with intra- and subretinal fluid, Hcy above 12 μmol/L, RVP of at least 8
mm above the IOP, and an IOP between 10 and 20 mmHg was included in this study. All eyes received three
Injections of 0.05 ml aflibercept at one-month intervals as clinically indicated.
Read more: https://www.sciencedirect.com/science/article/pii/S2667376225000137
Source: Josef Flammer, Prof. Emeritus, University of Basel, Switzerland